Wall Street analysts highlight three Nasdaq-listed biotech firms as potential takeover targets following AbbVie’s $6.9B Apogee deal.
AbbVie’s pending $6.9 billion acquisition of Apogee Therapeutics has reignited biotech merger speculation, focusing attention on firms with late-stage immunology and oncology assets. The deal underscores big pharma’s appetite for clinical-stage targets with strategic fit and premium potential.
Analysts have identified three Nasdaq-listed biotech companies as likely M&A candidates, led by Syndax Pharmaceuticals, which boasts two FDA-approved drugs and 224% revenue growth. Nektar Therapeutics and another unnamed firm also feature on watchlists, with catalysts expected within 12 months that could trigger bids or revaluations.
The Apogee acquisition serves as a template for future deals, prioritizing late-stage clinical data, addressable markets, and immunology or oncology focus. Market caps remain a key factor, with room for premiums driving buyer interest.